@article{lamoth.etal_2022,
  title = {Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective},
  shorttitle = {Investigational Antifungal Agents for Invasive Mycoses},
  author = {Lamoth, Frederic and Lewis, Russell E. and Kontoyiannis, Dimitrios P.},
  year = {2022},
  month = jan,
  journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  pages = {ciab1070},
  issn = {1537-6591},
  doi = {10.1093/cid/ciab1070},
  abstract = {Treatment of invasive fungal infections (IFI) remains challenging, because of the limitations of the current antifungal agents (i.e. mode of administration, toxicity, drug-drug interactions), and the emergence of resistant fungal pathogens. Therefore, there is an urgent need to expand our antifungal armamentarium. Several compounds are reaching the stage of phase II or III clinical assessment. These include new drugs within the existing antifungal classes or displaying similar mechanism of activity with improved pharmacologic properties (rezafungin, ibrexafungerp) or first-in-class drugs with novel mechanisms of action (olorofim, fosmanogepix). Although critical information regarding the performance of these agents in heavily immunosuppressed patients is pending, they may provide useful additions to current therapies in some clinical scenarios, including IFI caused by azole-resistant Aspergillus or multi-resistant fungal pathogens (e.g. Candida auris, Lomentospora prolificans). However, their limited activity against Mucorales and some other opportunistic molds (e.g. some Fusarium spp.) persists as a major unmet need.},
  langid = {english},
  pmid = {34986246},
  keywords = {APX001,CD101,E1211,F901318,SCY078,VT-1129,VT-1161,VT-1598},
  note = {Cited By :5
\par
Cited By :5
\par
Export Date: 20 November 2022
\par
Export Date: 20 November 2022}
}

{"_id":"n7DGRTXZyqGzEaZLf","bibbaseid":"lamoth-lewis-kontoyiannis-investigationalantifungalagentsforinvasivemycosesaclinicalperspective-2022","author_short":["Lamoth, F.","Lewis, R. E.","Kontoyiannis, D. P."],"bibdata":{"bibtype":"article","type":"article","title":"Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective","shorttitle":"Investigational Antifungal Agents for Invasive Mycoses","author":[{"propositions":[],"lastnames":["Lamoth"],"firstnames":["Frederic"],"suffixes":[]},{"propositions":[],"lastnames":["Lewis"],"firstnames":["Russell","E."],"suffixes":[]},{"propositions":[],"lastnames":["Kontoyiannis"],"firstnames":["Dimitrios","P."],"suffixes":[]}],"year":"2022","month":"January","journal":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","pages":"ciab1070","issn":"1537-6591","doi":"10.1093/cid/ciab1070","abstract":"Treatment of invasive fungal infections (IFI) remains challenging, because of the limitations of the current antifungal agents (i.e. mode of administration, toxicity, drug-drug interactions), and the emergence of resistant fungal pathogens. Therefore, there is an urgent need to expand our antifungal armamentarium. Several compounds are reaching the stage of phase II or III clinical assessment. These include new drugs within the existing antifungal classes or displaying similar mechanism of activity with improved pharmacologic properties (rezafungin, ibrexafungerp) or first-in-class drugs with novel mechanisms of action (olorofim, fosmanogepix). Although critical information regarding the performance of these agents in heavily immunosuppressed patients is pending, they may provide useful additions to current therapies in some clinical scenarios, including IFI caused by azole-resistant Aspergillus or multi-resistant fungal pathogens (e.g. Candida auris, Lomentospora prolificans). However, their limited activity against Mucorales and some other opportunistic molds (e.g. some Fusarium spp.) persists as a major unmet need.","langid":"english","pmid":"34986246","keywords":"APX001,CD101,E1211,F901318,SCY078,VT-1129,VT-1161,VT-1598","note":"Cited By :5 \\par Cited By :5 \\par Export Date: 20 November 2022 \\par Export Date: 20 November 2022","bibtex":"@article{lamoth.etal_2022,\n title = {Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective},\n shorttitle = {Investigational Antifungal Agents for Invasive Mycoses},\n author = {Lamoth, Frederic and Lewis, Russell E. and Kontoyiannis, Dimitrios P.},\n year = {2022},\n month = jan,\n journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},\n pages = {ciab1070},\n issn = {1537-6591},\n doi = {10.1093/cid/ciab1070},\n abstract = {Treatment of invasive fungal infections (IFI) remains challenging, because of the limitations of the current antifungal agents (i.e. mode of administration, toxicity, drug-drug interactions), and the emergence of resistant fungal pathogens. Therefore, there is an urgent need to expand our antifungal armamentarium. Several compounds are reaching the stage of phase II or III clinical assessment. These include new drugs within the existing antifungal classes or displaying similar mechanism of activity with improved pharmacologic properties (rezafungin, ibrexafungerp) or first-in-class drugs with novel mechanisms of action (olorofim, fosmanogepix). Although critical information regarding the performance of these agents in heavily immunosuppressed patients is pending, they may provide useful additions to current therapies in some clinical scenarios, including IFI caused by azole-resistant Aspergillus or multi-resistant fungal pathogens (e.g. Candida auris, Lomentospora prolificans). However, their limited activity against Mucorales and some other opportunistic molds (e.g. some Fusarium spp.) persists as a major unmet need.},\n langid = {english},\n pmid = {34986246},\n keywords = {APX001,CD101,E1211,F901318,SCY078,VT-1129,VT-1161,VT-1598},\n note = {Cited By :5\n\\par\nCited By :5\n\\par\nExport Date: 20 November 2022\n\\par\nExport Date: 20 November 2022}\n}\n\n","author_short":["Lamoth, F.","Lewis, R. E.","Kontoyiannis, D. P."],"key":"lamoth.etal_2022","id":"lamoth.etal_2022","bibbaseid":"lamoth-lewis-kontoyiannis-investigationalantifungalagentsforinvasivemycosesaclinicalperspective-2022","role":"author","urls":{},"keyword":["APX001","CD101","E1211","F901318","SCY078","VT-1129","VT-1161","VT-1598"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/a6GBPjh3wXfA46RXX/CV.bib","dataSources":["jKN7prtxaY9N8vqst","qLqjc4bwMYLmk2F3c","8E62bsJiEchQrmW6z"],"keywords":["apx001","cd101","e1211","f901318","scy078","vt-1129","vt-1161","vt-1598"],"search_terms":["investigational","antifungal","agents","invasive","mycoses","clinical","perspective","lamoth","lewis","kontoyiannis"],"title":"Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective","year":2022}